BAUDETTE, Minn., Oct. 29, 2019 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an experienced
specialty pharmaceutical and contract development &
manufacturing organization (CDMO), today announced the launch of
its new CDMO brand, ANI Global Source. This action follows
the integration of WellSpring Pharma Services, acquired one year
ago, and demonstrates the progress the company has made since the
acquisition. ANI Global Source is a specialty CDMO
supporting late stage development and commercial manufacture of
pharmaceutical products including tablets & capsules, liquid
solutions, suspensions, topical liquids, creams and gels with
unique expertise in hormones, potent compounds, and controlled
substances. ANI Global Source will continue to leverage its
robust infrastructure including over 300 employees and 270,000
square feet of manufacturing and packaging facilities across
multiple sites.
The launch of ANI Global Source will be highlighted by a new
website (www.aniglobalsource.com), logo, visual identity, and
series of brand communications culminating in a strong presence as
an exhibitor and sponsor of the CPhI Worldwide conference,
November 5-7, 2019 in Frankfurt, Germany. We look forward to
introducing ANI Global Source at CPhI Worldwide, and we believe it
truly represents our commitment and track record for on-time
delivery, exemplary quality, exceptional project management, and
broad scientific expertise.
ANI Global Source will be located at Booth #121H63 during the
CPhI Worldwide event.
Contact:
|
Russell
Miller
|
|
Senior Director,
Contract Sales
|
|
Russell.miller@anipharmaceuticals.com
|
|
919-407-1530
|
About ANI Global Source
ANI Global Source is a world-leading specialty CDMO
dedicated to supporting late stage development and commercial
manufacture of pharmaceutical products. With over 60 years of
experience and a 270,000 ft2 manufacturing and
packaging footprint, ANI Global Source's multiple sites
deliver on a wide range of pharmaceutical manufacturing needs,
including tablets & capsules (coated/uncoated), liquid
solutions, suspensions, topical liquids, creams and gels.
Additionally, the company offers unique expertise in manufacture of
hormones, potent compounds, and DEA Class II controlled substances.
Beyond the company's manufacturing capabilities, though, is a
demonstrated track record and ongoing commitment to exemplary
quality, on-time delivery, proactive project management and a
customer-centric approach to clear and effective
communication. Through the strong collaborative
relationships we have developed with clients, ANI Global
Source is a preferred partner that continues to deliver consistent
supply for patients.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products, financial position, operating results and
prospects, the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-the-launch-of-ani-global-source-its-contract-development-and-manufacturing-business-300946967.html
SOURCE ANI Pharmaceuticals, Inc.